language_icon
EN
HI

Gland Pharma Share price

GLAND

1741.9

7.20 (-0.41%)
NSE
BSE
Last updated on 10 Apr, 2026 | 15:45 IST
Today's High

1771.00

Today's Low

1732.00

52 Week Low

1342.00

52 Week High

2131.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Gland Pharma Chart

Gland Pharma Share Key Metrics

Volume
53183.00
Market Cap
28698.92 CR
LTQ@LTP
10@1741.90
ATP
1748
Var Margin
14.91 %
Circuit Range
1399.3-2098.9
Delivery %
44.53 %
Value
9.30 CR
ASM/GSM
No
Market Lot
1

Summary

At 10 Apr, 2026 | 15:45, Gland Pharma share price stands at ₹1741.9, showing a 7.20% -0.41 for the day. The stock’s intraday movement has stayed between ₹1732.00 and ₹1771.00, while on a 52-week basis it has fluctuated from ₹1342.00 to ₹2131.00.
In terms of trading activity, Gland Pharma has recorded a volume of 53183 shares, with a market capitalisation of ₹164756423. The stock’s Average Traded Price (ATP) stands at ₹174800, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 10,174190. The stock operates within a circuit range of ₹1399.3-2098.9, with a Value of ₹9.30 CR. The Delivery Percentage for the day is 44.53%. Additionally, Gland Pharma currently falls under the No framework, and trades with a market lot size of 1.

Gland Pharma Fundamentals

View More
P/E Ratio

33.96

P/B Ratio

2.93

Div. Yield

1.03

Sector P/E

62.26

Sector P/B

3.36

Sec. Div. Yield

0.58

Gland Pharma Resistance and Support

Pivot 1742.17

Resistance

First Resistance

1762.54

Second Resistance

1775.97

Third Resistance

1796.34

Support

First Support

1728.74

Second Support

1708.37

Third Support

1694.94

Gland Pharma Futures & Options

Data Not Found

Gland Pharma Shareholding Pattern

View More
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

51.83%

Mutual Fund

31.42%

Insurance

1.33%

Foreign Institutional Investors

7.58%

Domestic Institutional Investors

0.23%

Retail

7.61%

Others

0%

Total Promoters
MAR '25
51.83%
JUN '25
51.83%
SEP '25
51.83%
DEC '25
51.83%

Gland Pharma Corporate Actions

DateAgenda
2026-01-28Quarterly Results
2025-11-03Quarterly Results
2025-08-05Quarterly Results
2025-05-20Audited Results & Final Dividend
2025-02-03Quarterly Results

Gland Pharma News

Gland Pharma Limited

Gland Pharma has re-appointed Naina Lal Kidwai as a Non-Executive Independent Director for a new 5-year term starting May 17, 2026. This re-appointment ensures continuity of experienced leadership on the board.
Apr 09 2026 19:04:00

Gland Pharma Ltd - 543245 - Board Meeting Outcome for Reappointment Of Ms. Naina Lal Kidwai As An Independent Director, Subject To Shareholders Approval

Gland Pharma's Board re-appointed Ms. Naina Lal Kidwai as an Independent Director for a second five-year term, effective May 17, 2026. The re-appointment is subject to approval from the company members via postal ballot and e-voting.
Apr 09 2026 19:04:00
Read More

About Gland Pharma

NSE : 1186  
BSE : 543245  
ISIN : INE068V01023  

The Company was incorporated as ‘Gland Pharma Private Limited’ a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. Subsequently the name of the Company was changed to ‘Gland Pharma Limited’ pursuant to a special resolution passed by the shareholders of the Company on December 5 1994 and a fresh certificate of incorporation dated April 25 1995 was issued by the Registrar of Companies Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act 1956.Major events and milestones of the Company :2019- Filed Dexrazoxane for Injection the first filing with the National Medical Products Administration China and received clinical waiver2018- Received ANDA approval for Enoxaparin Sodium Injection USP for the US market- Received ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP 0.1% the first Ophthalmic product approval2017- Fosun Singapore acquired 74% stake in the Company2016- Obtained USFDA approval for the facilities at Jawaharlal Nehru Pharma City Visakhapatnam- Obtained USFDA approval for the manufacturing facility at Pashamylaram- Obtained USFDA approval for the facility at the Visakhapatnam Special Economic Zone2014- Obtained USFDA approval for small volume parenteral manufacturing facility at Visakhapatnam- Commissioned the Pashamylaram Unit-II manufacturing facility- Received the ‘Certificate of GMP Compliance of a Manufacturer’ from MHRA (UK) for manufacturing facility at Dundigal- Capital infusion of US$ 100 million into the Company pursuant to private equity investment aggregating to approximately US$ 200 million with KKR Floorline Investment Pte Ltd2012- Received the ‘Certificate of GMP Compliance of a Manufacturer’ from BGV Hamburg (Germany) for the manufacturing facility at Dundigal2010- Launched Heparin Sodium Injection in the US2007- Capital infusion of approximately Rs.1000 million into the Company pursuant to private equity investment aggregating to approximately Rs.1200 million with EILSF Co-Invest I LLC2004 - 2005- Launch of Enoxaparin Sodium Injection (Cutenox) in India and Rest of the world markets2003- Received USFDA approval for the manufacturing facility at Dundigal2000- Set up the in-house R&D facility at Dundigal Hyderabad1978- Incorporation of the Company by P.V.N. RajuAwards accreditations and recognitions received by the Company :2019- The Company was awarded the “Best Exporter” by the Hyderabad Customs- The Company was awarded the “Express Pharma Excellence Awards 2019” under the turnover base Rs. 500 – 2000 crore category organized by the Express Pharma and Optel Group- The Company was awarded the “Telangana Best Employer Brand Award” at the 14th Employer Branding Awards organised by the Employer Branding Institute India2018- The Company was awarded the “Top Exporter” by the Hyderabad Customs Customs and Central Excise Government of India- The Company was awarded the “Outstanding Export Performance Award” under Formulations Silver Star category by Pharmaceuticals Export Promotion Council of India2017- The Company was awarded the “Excellence in Export Performance” at the Federation of Telangana and Andhra Pradesh Chambers of Commerce and Industry instituted by Surana Group of Industries Secunderabad- The Company was awarded the “Outstanding Export Performance Award” under Formulations Fast Growing -1 category by Pharmaceuticals Export Promotion Council of India2016- The Company was awarded the “Top Exporter/Importer” by the Hyderabad Customs Commissionerate Customs and Central Excise Government of India2014- The Company was awarded the “Outstanding Exports Performance Award” under the Regional (America and Oceania) category by Pharmaceuticals Export Promotion Council of India- The Company received the BS OHSAS 18001:2007 certifying the occupational health and safety management system of the manufacturing facility at Dundigal- The Company received ISO 14001:2015 certifying the environmental management system of the manufacturing facility at Dundigal- The Company received ISO 9001:2015 certifying the quality management system of manufacturing facility at Dundigal

Read More

Gland Pharma Management

NamePosition
Mr. Srinivas Sadu Executive Chairman
Mr. Wenjie Zhang Non Exe.Non Ind.Director
View More

Gland Pharma FAQs

The Buying Price of Gland Pharma share is 1741.9 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Gland Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Gland Pharma, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Gland Pharma shares is 33.96. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Gland Pharma shares is 2.93. Useful to assess the stock's value relative to its book value.

To assess Gland Pharma’s valuation compare Sector P/E, P/B which are 62.26 & 3.36 with sector averages, along with growth rates and financial metrics.

The Market Cap of Gland Pharma is 28698.92 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Gland Pharma share price is 2131.00 & 1342.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Gland Pharma belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost